Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration
2003; Elsevier BV; Volume: 110; Issue: 5 Linguagem: Inglês
10.1016/s0161-6420(03)00095-2
ISSN1549-4713
Autores Tópico(s)Angiogenesis and VEGF in Cancer
ResumoPharmacologic inhibition of angiogenesis represents a novel approach in the treatment of choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD). Various components of the neovascular process, including growth factor expression, represent potential targets for modulation by drug therapies. Vascular endothelial growth factor (VEGF) has been demonstrated in human specimens of CNV, 1 Kvanta A. Algvere P.V. Berglin L. Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996; 37: 1929-1934 PubMed Google Scholar and animal models have confirmed that this protein is capable of inducing CNV. 2 Baffi J. Byrnes G. Chan C.C. Csaky K.G. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2000; 41: 3582-3589 PubMed Google Scholar Therefore, targeted inhibition of VEGF seems to be a reasonable approach for the treatment of CNV.
Referência(s)